Vetter and Rentschler Biopharma agreed to collaborate to enhance their CDMO services and offer complementary skills and experience along the biopharmaceutical value chain. The goal is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.

“We are pleased to collaborate with such a highly respected and successful company. Like us, Vetter is a family-run and well-established service provider,” said Nikolaus F. Rentschler, PhD, chairman of the board of Rentschler. “We have known each other for many years and share a commitment to high quality standards and sustainable value creation.”

“Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before.”

“It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA,” added Senator h.c. Udo J. Vetter, chairman of the advisory board of Vetter. “The alignment of Rentschler Biopharma’s experience in drug substance manufacturing and our own core competency in drug product pharmaceutical manufacturing is yet another opportunity to pursue.”

The alliance will leverage Rentschler Biopharma’s experience in drug substance manufacturing, including bioprocess development and API production, and Vetter’s expertise in aseptic fill and finish and secondary packaging, according to officials at both companies. They pointed out that they have already identified opportunities, where early and active exchange of know-how and best-practice will benefit both clients and their drug products. Over the next months, these opportunities are expected to be further validated in pilot client projects with joint teams from both companies.

“We are excited to team up with Vetter to complement our customized development and manufacturing solutions for even the most complex biopharmaceuticals,” noted Frank Mathias, PhD, CEO of Rentschler Biopharma, said. “Vetter is adding a wealth of expertise for clinical and commercial drug product supply, well suited to the maturing product pipeline of our clients. Their services are a great fit to our own offering. Our collaboration holds great promise for further simplifying client solutions, while expanding the boundaries of what is possible in biopharmaceutical production.”

Both companies will continue to independently address and service current and new clients as they explore opportunities for cooperative integration of approaches to complex molecules in today’s rapidly evolving global healthcare environment, explained Mathias.

This site uses Akismet to reduce spam. Learn how your comment data is processed.